About the Project
We invite applications for a three and a half-year industry funded PhD studentship to work under the supervision of Prof Mark Dickman at the University of Sheffield in collaboration Dr Christina Vanhinsbergh (AstraZeneca) and Dr Ken Cook (ThermoFisher).
Oligonucleotide therapeutics are an exciting new class of treatments for human disease. The recent success of a number of oligonucleotide therapeutics have marked important milestones in the recognition of oligonucleotides as therapeutic agents capable of competing with traditional drugs like small molecules and monoclonal antibodies.
High Performance Liquid Chromatography (HPLC) with UV detection is currently one of the most widely adopted analytical methods used for purity testing and is often used in combination with mass spectrometry. Significant challenges remain in developing sensitive HPLC and mass spectrometry methods that enable the identification of low level impurities, are suitable for the analysis of a wide range of chemically modified and conjugated oligonucleotide therapeutics that are difficult to separate. There are still significant limitations to single dimension chromatographic approaches as common impurities of interest are often difficult to resolve. This is especially the case for phosphothiolated oligonucleotides where thousands of diastereoisomeric impurities are present. The need for additional chromatographic resolving power to identify and/or quantify these impurities is extremely important.
Multidimensional chromatography (typically 2D-LC) offers a potential solution to address this complex issue and conveniently offers chromatographic orthogonality in a single workflow. This project aims to develop 2D liquid chromatography for the analysis of oligonucleotide therapeutics. A wide range of training will be provided during the PhD studentship including training in 1D HPLC, 2D HPLC and mass spectrometry.
AstraZeneca have funding to support a PhD studentship in collaboration with the University of Sheffield which will cover PhD stipend and fees for 3.5 years. This is a prestigious industry funded PhD studentship which is supported by the global pharmaceutical company AstraZeneca, who will enhance its tax-free stipend to approx. £19,000 p.a (subject to annual increase) and will provide a period of placement within the company’s research laboratories.
Funding Notes
3.5 year fully-funded programme of research and skills training, starting October 2023, the funding includes:
• Research stipend provided by AstraZeneca (estimated £19,500 per year).
• Tuition fees at the UK fee rate (£4,473 per year).
• Research training and support grant (RTSG).
For more information contact:





Reviews
There are no reviews yet.